Dr. Oki is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
1515 Holcombe Blvd Unit 429
Houston, TX 77030Phone+1 713-563-6705
Education & Training
University of Texas Health Science Center at HoustonFellowship, Hematology and Medical Oncology, 2003 - 2006
Icahn School of Medicine at Mount Sinai/Morningside/WestResidency, Internal Medicine, 2000 - 2003
Graduate School of Medicine and Faculty of Medicine, The University of TokyoClass of 1998
Certifications & Licensure
TX State Medical License 2010 - 2026
CA State Medical License 2017 - 2025- American Board of Internal Medicine Internal Medicine
- American Board of Internal Medicine Hematology
- American Board of Internal Medicine Medical Oncology
Clinical Trials
- Efficacy of the HCVIDDOXIL Regimen in Patients With Newly Diagnosed Peripheral T-Cell Lymphoma Start of enrollment: 2003 Sep 01
- SAHA + CHOP in Untreated T-cell Non-Hodgkin's Lymphoma Start of enrollment: 2008 Nov 01
- Panobinostat (LBH589) Plus Everolimus (RAD001) in Patients With Relapsed and Refractory Lymphoma Start of enrollment: 2009 Nov 01
- Join now to see all
Publications & Presentations
PubMed
- 41 citationsEpigenetic Mechanisms in AML – A Target for TherapyYasuhiro Oki, Jean Pierre J. Issa
Cancer Treatment and Research. 2009-01-01 - 537 citationsResults of a randomized study of 3 schedules of low-dose decitabine in higher-risk myelodysplastic syndrome and chronic myelomonocytic leukemiaHagop M. Kantarjian, Yasuhiro Oki, Guillermo Garcia-Manero, Xuelin Huang, Susan O'Brien
Blood. 2007-01-01 - 254 citationsObjective responses in relapsed T-cell lymphomas with single-agent brentuximab vedotinSteven M. Horwitz, Ranjana H. Advani, Nancy L. Bartlett, Eric D. Jacobsen, Jeff P. Sharman
Blood. 2014-05-15
Journal Articles
- Rituximab with ABVD vs ABVD for Advanced Stage High-Risk Classical Hodgkin Lymphoma: A Randomized Phase II StudyFrancesco Turturro, Luis E Fayad, Anas Younes, Michelle Fanale, Yasuhiro Oki, Hun Ju Lee, Nancy L Bartlett, Haematologica
Abstracts/Posters
- Smart Start: Rituximab, Lenalidomide, and Ibrutinib Alone and in Combination with Standard Chemotherapy for Patients with Newly Diagnosed Diffuse Large B-Cell Lymphoma...Yasuhiro Oki, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
Lectures
- Older Patients (pts) with Previously Untreated Classical Hodgkin Lymphoma (cHL): A Detailed Analysis from the Phase 3 ECHELON-1 Study2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
- Tenalisib, a dual PI3K δ/γ inhibitor: Safety and efficacy results from an on-going phase I/Ib study in relapsed/refractory T-cell lymphoma.2018 ASCO Annual Meeting - Chicago, Illinois - 06/4/2018
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
